Pharmacogenomics, the study of how genetic variation across the whole genome impacts drug response, can help guide diagnosis and therapies [Stevens, 2021]. Pharmacogenomics encompasses proteomics, transcriptomics, metabolomics and metagenomics, and analysis of these genetic factors, as well as personal and environmental factors, increasingly involves artificial intelligence to cope with the extreme data complexities [Sadee, 2023]. The aim of pharmacogenomics is to optimize health care for individual patients with the use of predictive biomarkers to improve outcomes and prevent adverse effects from medication [Sadee, 2023]. Pharmacogenomic evidence suggests that the response to rhGH is  polygenic [Dauber, 2020], and the level of knowledge surrounding the response to rhGH should enable the development of a pretreatment blood test to predict an individual’s response to treatment [Stevens, 2021]. Pharmacogenomics, both in general, and for growth disorders, is a powerful tool, but clinical application of findings has limitations including unknown validity of findings across ethnic groups, underlying bias in healthcare and real-world validation [Sadee, 2023]. The aim of this podcast is to increase the current state of knowledge of the research into pharmacogenomics in growth disorders, and how it can be extrapolated to clinical practice to enhance personalization and precision of treatment of patients.